Investigational drug · Phase 3
BE1116
Also called: 4F-PCC
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Complex Cardiovascular Surgery With Cardiopulmonary Bypass.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "BE1116"
First trial start
2025
Sep 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BE1116", any sponsor or status.
Conditions studied
As listed on its trial records.
- Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "BE1116" as an intervention, largest first.
- Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )Pivotal-lookingTerminated
CSL BehringIndustry
NCT05568888 · 1,366 participants · Start Mar 28, 2023 · Primary completion Oct 29, 2024
Drug: BE1116; Placebo · For: Traumatic Injury
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 113 sites in all
- Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)Pivotal-lookingRecruiting
CSL BehringIndustry
NCT07094087 · 200 participants (planned) · Start Sep 15, 2025 · Primary completion Apr 6, 2027
Drug: BE1116; FFP · For: Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Sites: Los Angeles, California; Atlanta, Georgia; Chicago, Illinois · 24 sites in all
- Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese SubjectsPivotal-lookingCompleted
CSL BehringIndustry
NCT02281201 · 11 participants · Start Oct 2014 · Primary completion Jan 2016
Drug: BE1116 (Prothrombin Complex Concentrate) · For: Acute Major Bleeding; Reversal of Coagulopathy
Sites: Sendagi, Japan; Chūōku, Japan; Kamagari, Japan · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Urgent reversal of factor Xa inhibitors in emergent neurosurgery: A retrospective comparative study of 4F-PCC and andexanet alfa.
Alok K, Lin A, Ohanesian L, et al. · Clin Neurol Neurosurg 2026
- A Retrospective Evaluation of Safety Outcomes of Four-Factor Prothrombin Complex Concentrate & Tranexamic Acid Versus Four-Factor Prothrombin Complex Concentrate Alone in Patients Requiring Emergent Anticoagulation Reversal.
Yagodinski AP, Tong SR, Holtzapple CB, et al. · J Pharm Pract 2026
- Evaluation of Four-Factor Prothrombin Complex Concentrate Dosing for Major Bleeding Following Cardiac Surgery.
Mullinax BT, Pinkos K, Dilawri A, et al. · J Pharm Pract 2026
- Evaluation of coagulation factor concentrates for persistent bleeding after cardiothoracic surgery.
Hartwig MF, Hirschy R, Meckel J · Am J Health Syst Pharm 2026
- Managing Pediatric Acquired Hemophilia A When Guideline-Recommended Bypassing Agents Are Unavailable: A Case Report.
Zhang L, Guo XL, Xiao JW, et al. · J Clin Med 2026
- Intravenous thrombolysis in acute ischemic stroke after reversal of warfarin anticoagulation in patients with mechanical heart valve prostheses and an INR > 1.7.
Neumann J, Cernik D, Bilik J · Front Neurol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.